Page last updated: 2024-10-22
antipyrine and Ambulation Difficulty
antipyrine has been researched along with Ambulation Difficulty in 1 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Our objective was to explore the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients with a Japan ALS severity classification of Grade 3." | 9.24 | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). ( , 2017) |
| "Our objective was to explore the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients with a Japan ALS severity classification of Grade 3." | 5.24 | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). ( , 2017) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner[NCT00415519] | Phase 3 | 25 participants (Actual) | Interventional | 2006-12-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: baseline and 24 weeks
| Intervention | percentage of FVC (Least Squares Mean) |
|---|
| MCI-186 | -18.75 |
| Placebo of MCI-186 | -15.69 |
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
"No primary endpoint was used, because various exploratory analyses were performed.~0=worst; 48=best" (NCT00415519)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|
| MCI-186 | -6.52 |
| Placebo of MCI-186 | -6 |
Percentage of Participants With Adverse Drug Reactions
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|
| MCI-186 | 23.1 |
| Placebo of MCI-186 | 8.3 |
Percentage of Participants With Adverse Events
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|
| MCI-186 | 92.3 |
| Placebo of MCI-186 | 100 |
Death or a Specified State of Disease Progression
"No primary endpoint was used, because various exploratory analyses were performed.~Any of death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding was defined as an event." (NCT00415519)
Timeframe: 24 weeks
| Intervention | events (Number) |
|---|
| death | disability of independent ambulation | loss of upper arm function | tracheotomy | use of respirator | use of tube feeding |
|---|
| MCI-186 | 1 | 4 | 1 | 0 | 0 | 1 |
,| Placebo of MCI-186 | 0 | 2 | 2 | 0 | 0 | 0 |
Percentage of Participants With Abnormal Changes in Sensory Examinations
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|
| Numbness | Staggering | Vibratory sensation |
|---|
| MCI-186 | 0 | 10 | 0 |
,| Placebo of MCI-186 | 0 | 0 | 0 |
The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|
| White blood cell count (WBC) | Other laboratory tests except for WBC |
|---|
| MCI-186 | 23.1 | 0 |
,| Placebo of MCI-186 | 8.3 | 0 |
Trials
1 trial available for antipyrine and Ambulation Difficulty